fbpx Home - Plus Therapeutics (PSTV)

dding millions more Abby hugs.

dding millions more Abby hugs.

dding millions more Abby hugs.

dding millions more Abby hugs.

Power and precision
in cancer
radiotherapeutics.

The power of precision in radiotherapeutics.

The power of precision in radiotherapeutics.

Radiation is considered one of the most powerful methods of destroying cancer for over a century. But even today, ways to deliver significant doses to a tumor without damaging normal surrounding tissue are few. We are breaking that barrier with our new class of targeted radiotherapeutics.

Leveraging novel drug formulations and technologies, our drugs are designed to deliver a single, safe and effective dose of radiation directly to the tumor in adults and children battling rare and difficult-to-treat cancers. Our precise approach has the potential to preserve normal cell and tissue functioning – and add more precious moments to each patient’s life.

Minimum Toxicity to
Healthy Cells

Combining innovative formulations with novel administration techniques, we can potentially insert a single radiation dose into just the tumor or affected tissue until the radiation dissipates and is safely cleared by the body.

Maximum Toxicity to
Cancer Cells

We have developed an innovative approach to encapsulating the radiation particle, Rhenium, and administering it in elevated doses that are potentially retained for long enough to overwhelm and potentially eliminate tumor cells.

Minimum Toxicity to
Healthy Cells

Minimum Toxicity to Healthy Cells

Minimum Toxicity to Healthy Cells

Combining innovative formulations with novel administration techniques, we can potentially insert a single radiation dose into just the tumor or affected tissue until the radiation dissipates and is safely cleared by the body.

Maximum Toxicity to
Cancer Cells

Maximum Toxicity to Cancer Cells

Maximum Toxicity to Cancer Cells

We have developed an innovative approach to encapsulating the radiation particle, Rhenium, and administering it in elevated doses that are potentially retained for long enough to overwhelm and potentially eliminate tumor cells.

The four components of our radiotherapeutic platform.

Rhenium

Rhenium radioisotopes emit relatively short-range beta rays for precisely targeting tumors, as well as gamma rays for live imaging throughout treatment.

Drug Loading

We have patents describing proprietary techniques for transporting and trapping isotopic Rhenium into nanoliposomes using a lipophilic chelator, BMEDA, for radionuclide therapy.

Nanoliposomes

Nanoliposomes are a safe and reliable way to encapsulate, deliver and retain radiation within a specific injection site.

Microspheres

We load radiolabeled nanoliposomes into biodegradable, embolic, alginate microspheres to create a novel delivery system.

Rhenium

Rhenium radioisotopes emit relatively short-range beta rays for precisely targeting tumors, as well as gamma rays for live imaging throughout treatment.

Drug Loading

We have patents describing proprietary techniques for transporting and trapping isotopic Rhenium into nanoliposomes using a lipophilic chelator, BMEDA, for radionuclide therapy.

Nanoliposomes

Nanoliposomes are a safe and reliable way to encapsulate, deliver and retain radiation within a specific injection site.

Microspheres

We load radiolabeled nanoliposomes into biodegradable, embolic, alginate microspheres to create a novel delivery system.

Our Programs

Rhenium-186 NanoLiposome (186RNL)

The first Rhenium-186 radiolabeled nanoliposome therapy, designed to target brain and CNS cancers in adults and children, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.

Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM)

A next-generation radioembolization therapy in which thousands of Rhenium-188 radiolabeled nanoliposomes are loaded into a single alginate microsphere to potentially treat a multitude of solid organ cancers, including two forms of liver cancer, hepatocellular carcinoma and metastatic colorectal cancer.

Rhenium-186 NanoLiposome (186RNL)

The first Rhenium-186 radiolabeled nanoliposome therapy, designed to target brain and CNS cancers in adults and children, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.

Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM)

A next-generation radioembolization therapy in which thousands of Rhenium-188 radiolabeled nanoliposomes are loaded into a single alginate microsphere to potentially treat a multitude of solid organ cancers, including two forms of liver cancer, hepatocellular carcinoma and metastatic colorectal cancer.